SQLite Web: event_store.db

Update row 1184 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-07T23:23:54.391414+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:e1c63f7f8b85addf","evidence_event_ids":["evt_63b545eedbed"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt","as_of":"2026-04-07T23:23:54.391414+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt","company":"SOLENO THERAPEUTICS INC","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_f4fdc847c7b0bf04","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt","content_type":"text/plain","enriched_at":"2026-04-07T23:49:55.309831+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"8-K","final_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt","source_event_id":"evt_63b545eedbed","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"33ff80d2a81fbb6d","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-05","2026-04-06","2026-04-07"],"entities":[{"asset_class":"equity","name":"Soleno Therapeutics, Inc.","relevance":"high","symbol":"SLNO","type":"issuer_company"},{"asset_class":"equity","name":"Neurocrine Biosciences, Inc.","relevance":"high","symbol":"","type":"acquirer_parent"},{"asset_class":"equity","name":"Sigma Merger Sub, Inc.","relevance":"high","symbol":"","type":"acquirer_subsidiary"},{"asset_class":"equity","name":"Soleno Therapeutics, Inc. common stock","relevance":"high","symbol":"SLNO","type":"security"}],"event_type":"merger_acquisition","information_gaps":["The 8-K item number(s) and exhibit list are not provided in the cleaned text.","No details are provided here on the specific merger agreement terms beyond the tender/merger structure and enumerated conditions.","No information is provided here on board recommendation, voting agreements, or regulatory approvals beyond the HSR waiting period condition.","The prior known state/delta versus earlier disclosures is not included in the provided text, so the exact change cannot be determined from this signal alone."],"key_facts":["Form 8-K (Current Report) filed by Soleno Therapeutics, Inc.","Date of report/earliest event reported: April 5, 2026.","Soleno entered into an Agreement and Plan of Merger with Neurocrine Biosciences, Inc. and Sigma Merger Sub, Inc.","Neurocrine will commence a cash tender offer to purchase all issued and outstanding Soleno common shares.","Offer price is $53.00 per share in cash, without interest, subject to applicable withholding taxes.","If the offer is successful, it will be followed by a merger where Soleno will continue as the surviving corporation and a direct wholly owned subsidiary of Neurocrine.","Purchaser\u2019s obligation to accept and pay is subject to conditions including: tendered shares (together with shares beneficially owned by Parent and subsidiaries) represent one more share than 50% of total shares outstanding at offer expiration; accuracy of company representations/warranties (with materiality exceptions); compliance with covenants; absence of a material adverse effect; termination/expiration of HSR waiting period; and other customary conditions.","The offer is not subject to any financing condition.","Parent and Purchaser are obligated to commence the offer within 10 business days of the merger agreement date and keep it open for 20 business days after commencement, subject to possible extension under the merger agreement.","At the effective time, each share (with specified exclusions, including shares owned by Parent/Purchaser/Company and shares with properly exercised appraisal rights) converts into the right to receive the offer price."],"numeric_claims":[{"label":"Offer price (per share)","value":"$53.00"},{"label":"Offer commencement timing","value":"within 10 business days from April 5, 2026"},{"label":"Offer duration after commencement","value":"20 business days"},{"label":"Tender condition threshold","value":"one more share than 50% of total shares outstanding (considering shares beneficially owned by Parent and subsidiaries)"}],"primary_claim":"On April 5, 2026, Soleno Therapeutics entered into a merger agreement under which Neurocrine Biosciences will commence a cash tender offer to purchase all outstanding Soleno shares for $53.00 per share.","relevance_score":0.9,"sentiment":"mixed","source_quality":"high","summary":"Soleno Therapeutics filed a Form 8-K announcing it entered into an Agreement and Plan of Merger with Neurocrine Biosciences and a wholly owned subsidiary to acquire Soleno via a cash tender offer. The tender offer is priced at $53.00 per share and would be followed by a merger if successful.","topics":["8-K filing","cash tender offer","merger agreement","acquisition","Hart-Scott-Rodino","DGCL appraisal rights"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 SOLENO THERAPEUTICS INC \u00b7 Filed 20260406","ticker":"SLNO","tickers":["SLNO"],"title":"SLNO filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel